劲方医药-B(GENFLEET-B,股票代码:02595)宣布,其核心在研药物GFH375正式迈入中国注册性III期临床研究阶段,针对的适应症为KRAS G12D突变型非小细胞肺癌(NSCLC)。
劲方医药-B(GENFLEET-B,股票代码:02595)宣布,其核心在研药物GFH375正式迈入中国注册性III期临床研究阶段,针对的适应症为KRAS G12D突变型非小细胞肺癌(NSCLC)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.